Analyst Stacy Ku from TD Cowen maintained a Buy rating on LENZ Therapeutics (LENZ – Research Report) and keeping the price target at $60.00.
Stacy Ku has given his Buy rating due to a combination of factors including the promising outlook for LENZ Therapeutics’ LNZ100 eye drop, which is poised for FDA approval by August 2025. The product has shown exceptional efficacy and safety in trials, setting it apart in the presbyopia market, which is currently underserved by existing treatments like Vuity that have limitations in tolerability and duration of effect.
The enthusiasm from key opinion leaders and optometrists further supports the potential success of LNZ100, as it offers a differentiated mechanism of action without the safety concerns associated with other therapies. Additionally, the company’s strategic preparations for the product launch, including prescriber engagement and consumer awareness campaigns, are expected to drive significant market adoption. The anticipated high patient satisfaction and substantial market demand underscore the strong commercial prospects for LNZ100, justifying the Buy rating.
Questions or Comments about the article? Write to editor@tipranks.com